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ABSTRACT 
Background: Hepatitis C virus (HCV) infection is the most common blood- 
borne virus in the United States. Several mono- and combination therapies have 
been approved by the US Food and Drug Administration for the treatment of 
HCV, but their routes of administration, dosing approaches, eras of introduc- 
tion, and actual use in clinical practice and resulting effectiveness have not yet 
been reported. 
Objectives: The aim of this article was to characterize clinical use and viro- 
logic response (VR) of the HCV treatments interferon alfa-2b plus ribavirin (1FN + 
RBV) and peginterferon alfa-2b plus ribavirin (peg-IFN + RBV). 
Methods: This retrospective chart review of office-based practices in the 
United States was conducted at 200 physicians' offices across the United States. 
We collected ata concerning dosing patterns, VR (HCV RNA load, _< 1000 IU/mL or 
"negative" on polymerase chain reaction qualitative analysis), and adverse vents 
(AEs) from the medical records of a geographically diverse sample of patients 
receiving treatment for chronic HCV infection in the United States from July 2001 
to June 2002. For efficacy assessment, factors that were statistically different at 
baseline were adjusted using logistic regression. Providers also reviewed the med- 
ical records for symptoms or signs consistent with HCV treatment-related AEs. 
Results: Data from the records of 675 patients (423 men, 252 women; mean 
[SD] age of 45.5 [8.2] years; mean [SD] body weight, 80.8 [19.4] kg) were ana- 
lyzed. At baseline, the IFN + RBV treatment group (330 patients) had signifi- 
cantly higher percentages of black patients (22.1% vs 15.7%; P = 0.032) and 
patients with hepatic disease based on clinician-reported cirrhosis and liver 
dysfunction (18.8% vs 9.9%; P < 0.001), and a significantly lower percentage of 
white patients (60.3% vs 69.6%; P = 0.012) compared with the peg-IFN + RBV 
treatment group (345 patients). The difference in log-transformed baseline HCV 
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RNA loads between the 2 treatment groups in this study was <1 log unit. A sig- 
nificantly higher percentage of IFN + RBV-treated patients compared with peg- 
IFN + RBV-treated patients were prescribed HCV therapy on diagnosis (37.3% 
vs 29.9%; P = 0.041), and the mean (SD) duration of treatment was significantly 
different between the 2 treatment groups (52.5 [37.0] vs 27.5 [15.0] weeks; P < 
0.001). Peg-IFN + RBV was associated with a higher rate of VR compared with 
IFN + RBV on univariate analysis (28.5% vs 17.5%; P = 0.018). Recommended 
doses of peg-IFN and higher-than-recommended doses of RBV were associated 
with an increased likelihood of VR. Higher-than-recommended doses of peg-IFN 
without a concomitant increase in RBV was not associated with an increased 
likelihood of VR. The incidences of the 3 most commonly reported AEs in the 
IFN + RBV group were significantly higher compared with those in the peg- 
IFN + RBV group: fatigue, 217 (65.8%) versus 185 (53.6%) patients (P = 0.001); 
depression, 147 (44.5%) versus 120 (34.8%) (P -- 0.009); and anxiety, 87 (26.4%) 
versus 64 (18.6%) (P = 0.014). Nausea, however, was reported in a significantly 
higher number of patients in the peg-IFN group compared with the IFN + RBV 
group (74 [21.4%] vs 51 [15.5%]; P = 0.045). The frequencies of dose modifica- 
tion and treatment discontinuation due to AEs were similar between the 2 treat- 
ments and were similar to or less than those reported in other studies. 
Conclusions: In this retrospective data analysis of US office-based practices 
concerning HCV treatment, clinicians were observed to prescribe IFN + RBV at 
doses that differ from recommendations i  the product information (PI), as well 
as prescribe the RBV component of peg-lFN + RBV at doses that differed from 
PI recommendations. Although patients treated with peg-IFN + RBV appeared to 
achieve higher VR compared with those treated with IFN + RBV in our analysis 
of data from clinical practice, peg-IFN + RBV was associated with lower VR rates 
compared with those reported in clinical studies. (Curr Ther Res Clin Exp. 2005; 
66:433-450) Copyright © 2005 Excerpta Medica, Inc. 
Key words: hepatitis C, pegylated interferon, interferon alfa-2b and ribavirin, 
ribavirin, dosing, outcomes. 
INTRODUCTION 
Hepatitis C virus (HCV) is the most common blood-borne virus in the United 
States, affecting ~3.9 million individuals and resulting in -2.7 million chronic 
infections. ~-6 Worldwide, chronic HCV infection has an estimated prevalence of
~3%, with 150 million carriers. 6 It is thought that many (50%-95%) HCV-infected 
individuals in the United States are unaware of their serologic status until they 
become chronic carriers, 7 yielding higher prevalence rates. 8 Therefore, it is 
likely that the proportion of people with a duration of HCV infection of 20 years 
or more would increase significantly by the mid-2010s. 8 
Approximately 10% to 20% of patients with chronic HCV infection develop ro- 
gressive hepatic fibrosis, leading to cirrhosis, end-stage hepatic disease, and/or 
hepatocellular carcinoma within 20 years of HCV diagnosis) ,2 A number of risk fac- 
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tors are associated with HCV progression toward hepatic disease. The primary 
risk factors include "older age" at the time of infection, male gender, immunosup- 
pression (eg, secondary to H1V), concurrent chronic hepatitis B virus (HBV) infec- 
tion, and high levels of alcohol consumption (>30 g/d in men, >20 g/d in women). ~ 
Current standard-of-care therapy for HCV consists of treatment with peg- 
interferon in combination with ribavirin (RBV). In studies, interferon alfa in a 
pegylated formulation (ie, interferon chemically linked to a polyethylene glycol 
moiety) has been shown to be more effective compared with nonpegylated 
interferon. 1,9-23 Two pegylated, recombinant, interferon alfa formulations-- 
peginterferon alfa-2a and peginterferon alfa-2b--have been approved by the US 
Food and Drug Administration (FDA) as monotherapy or in combination with 
RBV for the treatment of chronic HCV infection in adults with compensated 
hepatic disease who are naive to interferon treatment. Peginterferon alfa-2b is 
administered on a weight-adjusted basis in combination with non-weight- 
adjusted RBV. FDA-approved labeling for peginterferon alfa-2a does not specify 
weight-adjusted dosing, but suggests weight-adjusted dosing for concomitantly 
administered RBV. 24,25 Both interferon alfa and RBV have been associated with 
dose-limiting toxicities, including neutropenia, thrombocytopenia, and depres- 
sion (with interferon), and anemia (with RBV). 24-29 
The standard outcome measures of the effectiveness of HCV treatments 
include sustained virologic response (SVR), defined as an undetectable serum 
HCV RNA load (<-50 IU/mL or _<100 copies/mL) at 24 weeks after discontinuation 
of therapy) Peginterferon alfa combination therapy has resulted in overall SVRs 
of 70% to 82% in patients infected with non-1 HCV genotypes (types 2-6) and 
41% to 51% in patients infected with HCV genotype 1.11'12'24'25 
Evaluation of virologic response (VR), defined as an undetectable HCV RNA load 
or a 2-log decrease from baseline in HCV viral load after 12 weeks of therapy, is 
helpful in identifying individuals who will not respond to further treatment. Failure 
to achieve VR has a high negative predictive value for achievement ofSVR. 1,24,25 
With the purpose of characterizing use and outcomes of available HCV treat- 
ments in clinical practice, we retrospectively examined dosing patterns, VR, 
and adverse events (AEs) for 2 interferon alfa-2b-based treatment regimens: 
interferon alfa-2b in combination with RBV (IFN + RBV) and peginterferon alfa- 
2b in combination with RBV (peg-IFN + RBV). These treatment regimens were 
the standard of care at the time of the study. 
MATERIALS AND METHODS 
This retrospective chart review of office-based practices in the United States 
was conducted at 200 physicians' offices selected from a national sample of 
hepatitis pecialists provided by the sponsor. 
Study Design, Patient Population, and Data Collection 
To ensure representation from a geographically diverse population of pa- 
tients with chronic HCV infection, 200 physicians were recruited from the Inter- 
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continental Marketing Services (IMS) list of interferon prescribers of a total of 
7707 US providers (IMS Prescription Tracking-Xponent, an informational prod- 
uct, received by subscription, containing information concerning location and 
prescribing information from US physicians, compiled weekly and monthly). 
Physicians were ranked, in descending order, by the number of interferon pre- 
scriptions written between July 2001 and June 2002, and were sent information 
packets describing the study. The physician's specialty and interferon prescrip- 
tion deciles tatus 2-1° were used as key sampling variables. For inclusion, physi- 
cians were required to have been treating at least 15 patients with HCV at the 
time of the study and have a practice that was at least 50% office based. 
Physicians who were affiliated with a pharmaceutical company (on retainer or 
paid consultants) or participated in a clinical trial or market research involving 
HCV within the 3 months before the study were excluded. The intention of 
selecting providers with a significantly office-based practice was to ensure that 
patients elected for inclusion represented a mix of acute, chronic, and community- 
based care and a range of stages of HCV disease severity and progression. 
During July and August of 2002, participating physicians reviewed their own 
patients' medical records to identify adults diagnosed with chronic HCV who 
had been seen in their respective practices. Each recruited physician was as- 
signed 2 calendar quarters between July 2001 and June 2002 from which to 
identify the last 6 consecutive HCV-diagnosed patients een in the office. Data 
concerning demographic characteristics, HCV treatment and dosing, selected 
laboratory procedures, and clinical outcomes were transcribed by the physi- 
cians from patient medical records onto data-collection forms. 
The study design and research protocol were reviewed and approved by the 
sponsor for compliance with ethics standards, and waivers of consent were 
obtained from an independent institutional review board. Each patient's record 
was abstracted by the respective provider, and aggregated data were provided for 
research purposes by an independent third party. To comply with confidentiality 
requirements, nopatient-identifiable information was collected from providers. 
When an interim review of the treatment patterns was performed on the data 
from the first 551 patients, it was noted that the sample included a preponder- 
ance of nontreated patients with HCV, including relatively few patients with con- 
comitant HIV infection. Thus, subsequent physicians were asked to provide 
data from patients treated specifically for HCV, including those who were con- 
currently infected with HIV. Data from 447 patients were collected after the 
interim review. 
Data-collection forms were randomly audited and checked against selected 
patient medical files by an independent data-collection organization (Market 
Certitude, LLC, Morristown, New Jersey). An audit for data uniformity, com- 
pleteness, accuracy, and patterns of completion relative to other data fields was 
performed on 20% of the physician samples ubmitted and demonstrated >97% 
accuracy with source documents. Physicians were paid an honorarium for each 
completed ata-collection form. 
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HCV Treatment Dosing 
The dosing recommendations i cluded in the product information (PI) for 
IFN + RBV 29 are 3 MIU SC TIW, and RBV 1000 mg/d (weight, _<75 kg) or 1200 mg/d 
(weight, >75 kg) PO in 2 divided doses. Recommended dosing for peg-IFN + RBV 
therapy is peg-IFN 1.5 Ilg/kg • wk 24 SC plus RBV 800 mg/d PO in 2 divided doses. 27 
To assess dosing treatment s rategies, the PI-recommended doses of each treat- 
ment were compared with the actual doses administered to patients. 
Virologic Response 
Serum HCV RNA loads at 24 + 6 weeks from the start of HCV therapy were 
used for analysis of VR, defined as HCV RNA load _<1000 IU/mL or a negative 
result on HCV polymerase chain reaction qualitative analysis (Amplicor, Roche 
Diagnostics, Indianapolis, Indiana). To be included in the VR analysis, patients 
must have reached the analysis target of 24 + 6 weeks of treatment. 
Multiple, stepwise logistic regression was used to explore the independent 
effect of treatment on VR while controlling for differences in relevant risk fac- 
tors between groups. The order of entry of factors into the stepwise regression 
models were those variables having a P of _<0.1. Variables entered into the 
model included gender, race (white vs nonwhite), age (_<45 vs >45 years), weight 
(_<78 vs >78 kg), HCV genotype (1 vs non-O, time from HCV diagnosis to initial 
therapy, actual treatment duration (weeks), hepatic disease severity (mild vs 
other), baseline HCV RNA load (_<725,000 vs >725,000 IU/mL), baseline alanine 
aminotransferase (ALT) quotient (_<3 vs >3), and treatment (peg-IFN + RBV vs 
IFN + RBV). Baseline ALT quotient was defined as the mean of the serum ALT lev- 
els before treatment divided by the upper limit of normal (35 U/L). 
The effect of modified osing of peg-IFN + RBV on VR was investigated using 
logistic regression analyses in 3 different peg-IFN dosing strategies: recom- 
mended ose 24 (vs low and high doses combined), low dose (vs recommended 
and high doses combined), or high dose (vs low and recommended doses 
combined). In these multivariate efficacy analyses of modified peg-IFN dosing 
regimens, the dose of RBV was also included as a covariate. 
Tolerability Assessment 
For assessment ofAEs, participating physicians were provided with a list of 
possible treatment-related AEs, generated from the PIs of products actively 
used at the time of the study, 24,27,29 and asked to identify which AEs they con- 
sidered treatment related based on their clinical judgment. Providers 
reviewed the medical records, and if symptoms or signs consistent with HCV 
treatment-related AEs were originally recorded, these were indicated on the 
data-collection form. Providers could enter additional HCV-related "free-text" 
AEs if they were captured in the medical record but not prelisted on the data- 
collection instrument. 
Hemoglobin (Hb) concentrations, platelet counts, and neutrophil counts 
obtained during the course of treatment were recorded. For the purpose of 
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analysis, accepted normal laboratory values were used to define the inci- 
dence and severity of the hematologic events of study-defined anemia, throm- 
bocytopenia, nd neutropenia, independent of investigator-reported AEs, as 
follows: anemia: Hb <13 g/dL for males, <12 g/dL for females; thrombocytope- 
nia: platelet count <130,000 cells/pL; neutropenia: bsolute neutrophil count 
<1000 cells/pL. Severe hematologic AEs were defined according to the criteria 
in the peg-IFN PI, 24 as follows: severe anemia: Hb <8 g/dL; severe thrombocy- 
topenia: platelet count <50,000 cells/pL; severe neutropenia: absolute neu- 
trophil count <500 cells/pL. 
The frequency of dosing modification and discontinuation of HCV therapy 
due to AEs were determined for each treatment group based on recorded 
events. It is important o note that this retrospective chart review did not 
supersede or preclude reporting AEs to manufacturers or to the FDA. All 
patients who entered the study and started IFN + RBV or peg-IFN + RBV HCV 
treatment were included in the tolerability analysis. 
Statistical Analysis 
Summary statistics for continuous variables included number of subjects, 
mean, median, SD, and minimum and maximum values. Categorical variables 
were summarized using patient counts and percentages, gender (female vs 
male), race (white vs nonwhite), HCV genotype (1 vs non-l), hepatic disease 
severity (mild vs other), and treatment (peg-IFN + RBV vs IFN + RBV). A 
Cochran-Mantel-Haenszel univariate test adjusted for baseline genotype was 
used to determine overall between-group differences in VR. AEs were summa- 
rized and compared using the ~2 or Fisher exact test. Analysis of variance was 
used to compare differences between continuous variables. Stepwise logistic 
regression was used to generate a final model. All statistical analyses were per- 
formed using SAS version 8.2 (SAS Institute Inc., Cary, North Carolina). 
RESULTS 
The sample of consecutively enrolled practitioners included 130 gastroenterol- 
ogists, 50 infectious disease specialists, and 20 hepatologists (mean duration of 
practice, 14 years). These physicians provided records from a total of 998 HCV- 
diagnosed patients for review. Of these individuals, 778 (78.0%) were treated for 
HCV and 220 (22.0%) were not treated. Of the treated patients, 330 (42.4%) were ini- 
tially prescribed IFN + RBV (203 men, 127 women; mean [SD] age, 46.0 [8.7] years), 
345 (44.3%) peg-IFN + RBV (220 men, 125 women; mean [SD] age, 45.0 [7.7] years), 
and 103 (13.2%) received other therapies. 
Of 778 patients who were treated, 666 had all dosing data available, whereas 
112 had at least 1 dosing-data element missing and therefore were excluded 
from the analysis. Also, 154 patients discontinued therapy for any reason. 
Nontreated individuals and those who received other therapies are not dis- 
cussed further. 
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Demographic and Clinical Characteristics 
The combined study population (675 patients) was predominantly male 
(62.7%) and white (65.0%), with a mean (SD) age of 45.5 (8.2) years and a 
mean (SD) body weight of 80.8 (19.4) kg. The majority (87.9%) were not con- 
comitantly infected with other hepatitis viruses. Most (417 [61.8%]) of the 
patients were diagnosed with HCV genotype 1, whereas 106 (15.7%) had an 
unknown genotype status. At baseline, the IFN + RBV treatment group had 
significantly higher percentages of black patients (22.1% vs 15.7%; P = 0.032) 
and patients with hepatic disease based on clinician-reported cirrhosis and 
hepatic dysfunction (18.8% vs 9.9%; P < 0.001), and a significantly lower 
percentage of white patients (60.3% vs 69.6%; P -- 0.012) compared with the 
peg-lFN + RBV treatment group (Table I). The difference in log-transformed 
baseline HCV RNA loads between the 2 treatment groups in this study was 
<1 log unit (P = 0.023). There were no significant differences between the 2 treat- 
ment groups with respect o HIV or HBV comorbidities. A significantly higher 
percentage of IFN + RBV-treated patients were prescribed HCV therapy on 
diagnosis compared with peg-IFN + RBV-treated patients (37.3% vs 29.9%; 
P = 0.041), and the mean (SD) duration of treatment was significantly dif- 
ferent between the 2 treatment groups (52.5 [37.0] vs 27.5 [15.0] weeks; 
P < 0.001). 
HCV Treatment Dosing 
Data concerning HCV treatment dosing were available for 325 (98.5%) of the 
IFN + RBV-treated patients and 341 (98.8%) of the peg-IFN + RBV-treated 
patients. 
Clinicians prescribed the 1FN component of IFN + RBV treatment in accor- 
dance with pI29-recommended doses (3 MIU TIW) in 322 of 325 (99.1%) patients 
in the IFN + RBV treatment cohort, whereas 3 (0.9%) patients received less-than- 
recommended doses. The RBV dosing component of this therapy was less con- 
sistent with p129-recommended doses: of 135 patients who weighed ___75 kg, 
25 (18.5%) received doses above (>1200 mg/d), and 21 (15.6%) received doses 
below (<800 mg/d) the p129-recommended doses of RBV. Of 190 patients who 
weighed >75 kg, 48 (25.3%) received doses of RBV below (<800 mg/d) that rec- 
ommended in the P129; the remaining patients (142/190 [74.7%]) were treated 
with recommended doses. 
In 234 of 345 (67.8%) patients in the peg-IFN + RBV group, the doses of both 
therapeutic components actually administered differed significantly from those 
recommended in the PI. 29 Initial weight-adjusted doses of peg-IFN differed from 
p124-recommended doses in 177 (51.9%) patients (120 [35.2%] patients, higher; 
57 [16.7%] patients, lower), with administered oses ranging from 25% to 88% 
above and 17% to 67% below the pI24-recommended dose of 1.5 pg/kg • wk 
(Figure 1). In the same treatment group, 238 (69.8%) patients received oses of 
RBV that were 25% to 75% higher than that recommended in the P127 (800 rag/d) 
(Figure 2). One (0.3%) patient received a dose of 600 mg/d RBV. 
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Table I. Demographic and clinical characteristics of the study patients (N = 675). 
IFN + RBV Peg-IFN + RBV 
Characteristic (n = 330) (n = 345) P 
Age, mean (SD), y 46.0 (8.7) 45.0 (7.7) 0.11 
Sex, no. (%) 
Male 203 (61.5) 220 (63.8) 0.55 
Female 127 (38.5) 125 (36.2) 
Weight, mean (SD), kg 82.3 (20.0) 79.4 (18.7) 0.052 
Race, no. (%)* 
White 199 (60.3) 240 (69.6) 0.012 
Black 73 (22.1) 54 (15.7) 0.032 
Other/unknown 58 (1 7.6) 51 (14.8) 0.324 
Concomitant disease, no. (%)* 
Cirrhosis 62 (18.8) 34 (9.9) <0.001 
HIV 46 (13.9) 38 (11.0) 0.25 
HBV 30 (9.1) 28 (8.1) 0.13 
HCV genotype, no. (%) 0.085 
1 204 (61.8) 213 (61.7) 
Non-1 62 (18.8) 90 (26.1) 
Unknown 64 (19.4) 42 (12.2) 
Prior liver transplantation, no. (%) 13 (3.9) 7 (2.0) 0.18 
Liver biopsy performed, no. (%) 270 (81.8) 280 (81.2) 0.76 
Hepatic disease severity, no. (%) <0.001 
Mild 106 (32.1) 160 (46.4) 
Moderate 121 (36.7) 98 (28.4) 
Severe 33 (10.0) 1 7 (4.9) 
Unknown 70 (21.2) 70 (20.3) 
HCV RNA load, 5.53 (0.99) 5.71 (0.72) 0.023 
mean (SD), Io 9 copies (n = 209) (n = 226) 
ALT concentration, 98.4 (62.0) 89.6 (73.2) 0.1 2 
mean (SD), IU/L (n = 274) (n = 288) 
ALT quotient, 2.81 (1.77) 2.56 (2.09) 0.12 
mean (SD) (n -- 274) (n = 288) 
Prescribed HCV therapy 
at diagnosis, no. (%) 123 (37.3) 103 (29.9) 0.041 
Treatment duration, 52.5 (37.0) 27.5 (15.0) <0.001 
mean (SD), wk (n = 330) (n = 335) 
(continued) 
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Table I. (Cont inued)  
IFN + RBV Peg-IFN + RBV 
Characteristic (n = 330) (n = 345) P 
Primary medical insurance, no. (%)* 0.12 
HMO/PPO 195 (59.1) 219 (63.5) 
Medicaid 53 (16.1) 42 (12.2) 
FFS 37 (11.2) 51 (14.8) 
Other 37 (11.2) 24 (7.0) 
Unknown 8 (2.4) 9 (2.6) 
IFN = interferon alfa-2b; RBV = ribavirin; peg-IFN = pegylated interferon alfa-2b; HBV = hepatitis B 
virus; HCV = hepatitis C virus; ALT = alanine aminotransferase; HMO = health maintenance organiza- 
tion; PPO = preferred provider organization; FFS -- fee for service. 
*Percentages may not add to 100% due to rounding. 
Ef f icacy 
Virologic Response at 24 + 6 Weeks of Treatment 
Five hundred twelve patients reached the analysis target of 24 +_ 6 weeks of 
treatment. The remaining 266 patients who had not yet reached 24 weeks post- 
treatment were excluded from the analysis. VR was noted in a higher propor- 
tion of peg-IFN + RBV-treated patients compared with IFN + RBV-treated patients 
in the univariate (28.5% vs 17.5%; P-- 0.018) and the multivariate (OR, 1.68; 
P = 0.028) analyses (Table IF). Logistic regression model covariates associated 
with VR included non-1 genotype (OR, 4.09; P < 0.001), lower baseline HCV RNA 
load (OR, 3.13; P < 0.001), white race (OR, 2.18; P = 0.006), and female gender 
(OR, 1.70; P = 0.024). 
Effects of Modified Dosing of Peg-IFN + RBV on Virologic Response 
Recommended Dose of Peg-IFN 
Administration of peg-IFN at the pI24-recommended dose was associated with 
an increased likelihood of VR (OR, 2.58; P = 0.012) (Table III), as was higher-than- 
recommended RBV dose (OR, 2.37; P-- 0.043). Other factors associated with 
an increased likelihood of VR included baseline HCV RNA load ___725,000 IU/mL 
(OR, 5.62; P < 0.001), non-1 genotype (OR, 5.44; P < 0.001), and female gender 
(OR, 2.42; e = 0.023). 
Lower-than-Recommended Dose of Peg-IFN 
There was no association found between the administration f a lower-than- 
recommended 24 ose of peg-IFN and the likelihood of VR, whereas higher-than- 
recommended RBV dose (OR, 2.23; 95% CI of OR, 1.01-5.18), baseline HCV RNA 
load _<725,000 IU/mL (OR, 4.74; P < 0.001), and non-1 genotype (OR, 4.81; P < 
0.001) seemed to be associated with the likelihood of VR. 
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Figure 1. Weight-dose relationship of the pegylated interferon alfa-2b (peg-IFN) 
component received by patients in the peg-IFN + ribavirin treatment group 
(n = 345). PI = product information. 24 
Higher-than-Recommended Doseof Peg-IFN 
Administration of a higher-than-recommended 24 dose of peg-IFN was not 
associated with an increased likelihood of VR. Factors that were associated 
with an increased likelihood of VR using this dosing strategy included higher- 
than-recommended RBV dose (OR, 2.24; 95% CI of OR, 1.02-5.24), baseline HCV 
RNA load ___725,000 IU/mL (OR, 5.76; P < 0.001), non-1 genotype (OR, 6.03; P < 
0.001), and female gender (OR, 2.22; P -- 0.035). 
Tolerability 
Clinician-Reported Adverse Events 
Three hundred forty-five and 330 patients receiving peg-IFN + RBV and IFN + 
RBV, respectively, were included in the tolerability analysis. Clinician-reported 
AEs that occurred in both treatment groups with a frequency of >10% includ- 
ed the following conditions: fatigue (402 [59.6%]), influenza-like symptoms 
(330 [48.9%]), depression (267 [39.6%]), anemia (216 [32.0%]), headache (174 
[25.8%]), myalgia (161 [23.9%]), anxiety (151 [22.4%]), weight loss (143 [21.2%]), 
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Figure 2. Weight-dose relationship of ribavirin (RBV) received by patients in the 
pegylated interferon alfa-2b + RBV treatment group (n = 345). (Product 
information [pI]27-recommended dose is 800 mg/d, regardless of body 
weight.) 
Table II. Factors associated with virologic response (hepatitis C virus [HCV] RNA load, 
<1000 IU/mL at 24 + 6 weeks of treatment), determined by logistic regression. 
Variable OR 95% CI P 
Non-1 genotype 4.09 2.49-6.76 <0.001 
Baseline serum HCV RNA load, 
_<725,000 IU/mL 3.13 1.95-5.06 <0.001 
White race 2.18 1.27-3.87 0.006 
Peg-IFN + RBV 1.68 1.06-2.68 0.028 
Female gender 1.70 1.07-2.70 0.024 
OR = odds ratio; peg-IFN = pegylated interferon alfa-2b; RBV = ribavirin. 
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insomnia (139 [20.6%]), musculoskeletal pain (125 [18.5%]), nausea (125 
[18.5%]), neutropenia (107 [15.9%]), fever (99 [14.7%]), injection-site reaction 
(96 [14.2%]), and alopecia (84 [12.4%]). The incidences of the 3 most commonly 
reported AEs in the IFN + RBV group were significantly higher compared with 
those in the peg-IFN + RBV group: fatigue, 217 (65.8%) versus 185 (53.6%) 
patients (P = 0.001); depression, 147 (44.5%) versus 120 (34.8%) (P = 0.009); and 
anxiety, 87 (26.4%) versus 64 (18.6%) (P = 0.014). Nausea, however, was reported 
in a significantly higher number of patients in the peg-IFN group compared with 
the IFN + RBV group (74 [21.4%] vs 51 [15.5%]; P = 0.045). 
Hematologic Adverse Events 
Statistically similar rates of anemia (33.0% vs 31.0%), thrombocytopenia 
(6.4% vs 8.7%), and neutropenia (15.2% vs 16.5%) were observed in the IFN + 
RBV and peg-IFN + RBV groups, respectively. The incidence of hematologic AEs 
defined as severe  included thrombocytopenia (4.5% with IFN + RBV, 2.3% with 
peg-IFN + RBV), neutropenia (<1% with IFN + RBV, 0 with peg-IFN + RBV), and 
anemia (<1% in both groups). 
Dose Modification and Treatment Discontinuation 
The frequencies of dose modification due to AEs were statistically similar 
between the 2 treatment groups (10.3% with IFN + RBV vs 11.3% with peg-IFN + 
RBV), as was the frequency of discontinuation of therapy due to AEs (10.6% 
vs 8.7%). 
Discontinuation of therapy due to depression was not statistically different 
between the IFN + RBV-treated patients and the peg-IFN + RBV-treated patients 
(9 [2.7%] vs 6 [1.7%]). 
Seventy-one of 330 (21.5%) patients treated with IFN + RBV and 11 of 345 
(3.2%) treated with peg-IFN + RBV switched from their initial HCV treatment 
to another HCV treatment during the study period. IFN + RBV-treated 
patients witched treatments due to poor response (42 [12.7%] patients), the 
availability of a new peginterferon alfa treatment (15 [4.5%]), AEs (11 [3.3%]), 
noncompliance (1 [0.3%]), or lack of insurance coverage or patient desire 
(1 [0.3%] each). Of the peg-IFN + RBV-treated patients who switched treat- 
ment, 7 (2.0%) switched due to an AE (6 due to anemia and 1 due to depres- 
sion), or lack of insurance coverage or efficacy (2 [0.6%] each). 
DISCUSSION 
This retrospective review of charts from patients with chronic HCV infection 
was designed to provide insight into patterns of use of IFN + RBV and peg-IFN + 
RBV therapies in clinical practice, and to explore the effects of dosing regimens 
outside P124,27,29 recommendations on drug effectiveness and tolerability. This 
study showed that IFN + RBV tended to be administered consistently with 
doses recommended in the PI, 29 but the same was not true for peg-IFN + RBV 
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therapy: clinicians treated fewer than half of patients with recommended 24 
doses of peg-IFN, and well over two thirds of patients with doses of RBV in 
excess of the recommended dose. 27 
The IFN + RBV treatment group had larger percentages of black patients and 
patients with severe hepatic disease at baseline compared with the peg-IFN + 
RBV treatment group; both of these are characteristics of patient populations 
who are more difficult to treat compared with other patient populations with 
HCV. 1,30,31 In addition, a significantly higher percentage of IFN + RBV-treated 
patients were prescribed HCV therapy at the time of diagnosis compared with 
peg-IFN + RBV-treated patients. This finding may reflect more prompt clinical 
intervention i more seriously ill patients, or it may be an epoch effect. Because 
IFN + RBV therapy became available in February 1991, its use might have coin- 
cided with a period during the 1990s when physicians viewed the diagnosis of 
HCV infection with more alarm. IFN + RBV-treated patients were treated for a 
longer mean duration compared with peg-IFN + RBV-treated patients, likely due 
to the timing of FDA approval of the use of IFN + RBV and peg-IFN (December 
2002 and January 2001, respectively) and the time period of data collection 
(July 2001 to June 2002). 
Treatment with the pI24-recommended dose of peg-IFN was associated with 
an increased likelihood of attaining VR, whereas the administration f higher or 
lower doses of peg-IFN did not significantly affect VR. Patients treated with 
higher-than-recommended doses of RBV in the peg-IFN + RBV group had a greater 
likelihood of achieving VR relative to those treated with the pI27-recommended 
dose. Patients who received peg-IFN + RBV treatment were also more likely to 
achieve VR compared with those treated with IFN + RBV, a finding that should 
be viewed in light of the risk factors (AEs) noted earlier. Other factors found to 
increase the likelihood of VR in logistic regression analysis were infection with 
virus of non-1 genotype, baseline HCV RNA load _<725,000 IU/mL, white race, and 
female gender. 
Interferon and RBV both have been associated with dose-limiting treatment- 
related AEs, the incidences of which generally do not differ significantly after 24 
or 48 weeks of therapy. In addition, these AEs usually resolve with dose reduc- 
tions or cessation of therapy. 24,25,29,32 Use of interferon, pegylated or nonpegy- 
lated, has been associated with AEs including neuropsychiatric (depression, anx- 
iety, insomnia, irritability, emotional lability, suicidal ideation), hematologic, and 
gastrointestinal events; fatigue; and influenza-like symptoms (myalgia, muscu- 
loskeletal pain, fever, malaise, headache). Other, less common, interferon-related 
AEs include injection-site r action, pruritus, alopecia, weight loss, and dyspepsia. 
RBV has been associated with cytopenia, especially hemolytic anemia. 24,25,29,32 
Given the manner and the timing in which data concerning AEs were col- 
lected in this study, our findings likely reflect a lower incidence of AE reporting 
than would be expected in prospective, controlled clinical trials. Because the 
methodology was a retrospective data analysis, providers were subjectively 
interpreting the relationship between the AE and the timing of the patient visit. 
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Whether these relationships were cause-effect or temporal was not controlled 
for, which limits the generalizability of the findings. The severity of AEs was not 
analyzed in this study. In this study, AEs that were more likely to occur in the 
IFN + RBV group included fatigue, depression, and anxiety. Both groups had 
lower AE rates compared with those reported in controlled clinical trials with 
more rigorous reporting requirements. 24,29 Although a direct comparison of AEs 
across studies cannot be made due to differences in study populations, design, 
and data-collection and reporting methodologies, it is noteworthy that the inci- 
dence of anemia, thrombocytopenia, and neutropenia were not statistically differ- 
ent between the 2 treatments, contrary to the nearly 3-fold greater frequency 
reported in the IFN + RBV P129 versus the peg-IFN 24 + RBV 27 PIs. The presence of 
these AEs, normally associated with RBV dosing, may reflect he higher doses of 
RBV prescribed in the peg-IFN + RBV treatment group. The incidence of "severe" 
thrombocytopenia w s higher (4.5% vs 1.0%) and that of severe neutropenia was 
lower (<1% vs 11%) in patients receiving IFN + RBV in this study compared with 
laboratory findings from 24- and 48-week clinical trials reported in the IFN + RBV 
PI. 29 In the peg-IFN + RBV treatment group, 2.3% of patients experienced severe 
thrombocytopenia compared with <1% in the peg-IFN + RBV P129 (48-week trial). 
There were no cases of severe neutropenia n the peg-IFN + RBV treatment group 
in this study, compared with a reported incidence of 4% in the PI. 29 Severe anemia 
was rare with both treatments in this study, consistent with PI reports. 24,27,29 
The frequencies of dose modification (10.3% in IFN + RBV-treated patients 
and 11.3% in peg-IFN + RBV-treated patients) and treatment discontinuation 
due to AEs (10.6% and 8.?%, respectively) were similar to or less than those 
reported in other studies. Manns et a111 reported ose-modification rates of 34% 
(IFN + RBV) and 42% (peg-IFN + RBV) and treatment-discontinuation rates of 
13% (IFN + RBV) and 14% (peg-IFN + RBV) due to any AE with 48 weeks of ther- 
apy. The PIs for IFN + RBV 29 and peg-IFN 24 + RBV 27 report rates of 26% and 42%, 
respectively, for dose modification, and rates of 19% and 10% to 14%, respec- 
tively, for discontinuation of therapy due to AEs. 24'27'29 
Peginterferon alfa-2a was not included in the present study because the 
treatment was not commercially available until the end of the year for which 
we collected data (July 2001 to June 2002). The focus of this study was to 
examine biases in prescribing and dosing of products that were the standard 
of care during the year for which data were collected. These same biases and 
confusion may persist, even with newer and more effective treatments. Many 
of the treatment regimens and patterns used during the year for which data 
were collected are still used. Patient characteristics and the comorbid condi- 
tions continue to be relevant, and differences in dosing (weight based vs time 
based) are still issues. 
Potential biases in this study are those associated with retrospective data 
collection and their interpretation by physicians in a chart-review process. 
Participating physicians were clinicians experienced in the treatment and man- 
agement of HCV (a mean of 14 years of practice) and were, by the definition of 
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study inclusion criteria, a subgroup that actively treated large numbers of 
patients with HCV but were not actively involved in clinical trials. Office-based 
practitioners were selected in an attempt to avoid hospital-based biases in drug 
dosing, timing, and treatment. Physician expertise and clinical experience with 
HCV treatment may be also an unrecognized confounding variable that con- 
tributed to the treatment success of patients treated with nonrecommended 
dosing regimens, and may not be a generalizable model applied to other 
providers. In addition, bias may have been introduced when the sampling crite- 
ria were modified uring the study, to actively increase the number of patients 
treated and patients concurrently infected with HIV. 
Although clinical benefits (VRs sustained 6 months after the cessation of 
therapy) have been seen with higher, weight-based doses (1000 or 1200 mg/d) 
of RBV in combination with peginterferon alfa-2a in patients with genotype 1 in- 
fection, 33 it has not been determined whether the clinical benefit of higher 
doses of RBV in combination with peg-IFN observed in this study would be sim- 
ilarly sustained. Dose modification, switching treatments, and discontinuation 
of treatment were not frequent in the studied patient population, suggesting 
that treatment-limiting AEs were not excessive, despite the clinical-use pattern 
of nonrecommended dosing regimens. 
CONCLUSIONS 
The results of this retrospective data analysis of patients receiving treatment for 
chronic HCV infection in the United States from July 2001 to June 2002 suggest that 
peg-IFN + RBV was more likely to produce VR at 24 _+ 6 weeks of treatment com- 
pared with IFN + RBV in the patients tudied. RBV administered athigher-than- 
recommended doses in combination with peg-IFN appeared to offer some clinical 
benefits (improved VR, 28.5%) to patients with chronic HCV infection. Administra- 
tion of a higher-than-recommended dose of peg-lFN without aconcomitant increase 
in RBV dose was not associated with an increased likelihood of VR. 
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